AstraZeneca, a multinational pharmaceutical company has made a $700 million drug deal for cancer with Inovio. The deal is the third deal for the week made by the company.

The London-based company is aiming for the sole rights over an immune boosting medicine which it bought from Inovio. The latter received an initial payment of $27.5 million which serves as a down payment for the $700 million total amount.

AstraZeneca is currently studying a drug named INO-3112 which is now in the first and second phases of its clinical trials. The research team of the company is examining the drug along with other medicines that can be used for immune therapy.

The INO-3112 drug can potentially eradicate the type 16 and 18 HPV. If the study of the drug becomes successful, cure for deadly cancer disease.

Cancer has been making mankind suffer for years. For decades, experts have invested in a lot of money, time and effort to find a cure and alternative medicine, radiotherapy and chemotherapy for the disease.

Since there is a tough competition in the market, AstraZeneca has to provide results in a continuous manner to stay ahead of the competing companies. Besides the immune boosting medicine, the company has also signed for other deals for cancer treatment.

The drugs which the company are now studying will change the course of history. Eradicating cancer will benefit mankind in a tremendous way. Patients suffering from the disease will no longer have to fear losing their lives because of the abnormal cell growth.

Scientists are also hoping to develop a vaccine for cancer in the near future. Just like depression and obesity, the disease has affected many people and will continue to do so until it is eradicated. Through continues years of unending research, experts will achieve their goal.